We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Beneficial Mutation Dissociates Obesity from Diabetes

By LabMedica International staff writers
Posted on 23 Dec 2009
A potentially beneficial mutation has been identified that seems to dissociate obesity from the danger of developing type II diabetes.

Although some 20 to 30% of obese individuals fail to progress to diabetes, and while some nonobese individuals do develop the disease, the current report is perhaps the first to link these observation to the action of a specific gene.

Investigators at the Boston University School of Medicine (MA, USA) discovered a mutation of the Brd2 (Bromodomain-containing protein 2) gene in a population of laboratory mice. More...
These animals became severely obese but did not go on to develop type II diabetes. Specifically, reduced function of the Brd2 gene enhanced glucose tolerance; elevated adiponectin; increased the weight of brown adipose tissue; increased heat production and expression of mitochondrial uncoupling proteins in brown adipose tissue; reduced macrophage infiltration in white adipose tissue; and lowered blood glucose, leading to an improved metabolic profile and avoiding eventual type II diabetes.

These findings were published in the November 2, 2009, online edition of The Biochemical Journal (BJ) where the authors also noted that Brd2 was highly expressed in pancreatic beta cells, where it normally inhibits beta-cell mitosis and insulin transcription.

Senior author Dr. Gerald Denis, assistant professor of pharmacology and medicine at the Boston University School of Medicine, said, "Studies have shown that these individuals [obese but free of type II diabetes] have a reduced "inflammatory profile". Inflammation caused by normal immune cells called macrophages leads to insulin resistance and type II diabetes - this inflammation is typically seen in connection with obesity but it is the inflammation that is a trigger for diabetes, not the obesity itself. The mechanisms that explain this protection from diabetes are not well understood. Much like these protected obese humans, the Brd2-deficient mice have reduced inflammation of fat and never develop failure of the beta cells in the pancreas that is associated with type II diabetes."

"The strong influence of Brd2 levels on insulin production and action suggest that Brd2 is likely to be a promising target for diabetes treatment, but also imply that overactive Brd2 might cause diabetes," said Dr. Denis. "The ways in which Brd2 affects the immune system may also play a part in type I diabetes; further studies to determine this are needed."

Related Links:
Boston University School of Medicine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.